SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against uniQure N.V.

Core Viewpoint - A shareholder has filed a securities class action lawsuit against uniQure N.V. on behalf of investors who purchased shares between September 24, 2025, and October 31, 2025, alleging misrepresentations regarding the drug AMT-130, which was being developed for Huntington's Disease [1][5]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements about AMT-130, impacting the company's stock value [5]. - Investors who acquired uniQure shares during the specified period may be eligible to join the class action [2][3]. - The deadline to file as a lead plaintiff is April 13, 2026, and participation does not require serving as a lead plaintiff [4]. Group 2: Legal Representation - Bernstein Liebhard LLP, the law firm handling the case, has a history of recovering over $3.5 billion for clients and has been recognized for its litigation success [6]. - All representation in this lawsuit is on a contingency fee basis, meaning shareholders will not incur fees or expenses unless there is a recovery [4].